Genetic studies indicate a potential target 5-HTR3B for Drug Therapy in Schizophrenia Patients

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 159 B, Issue 8, 2012, Pages 1006-1008

  Gupta, Meenal ^a   Jain, Sanjeev ^b   Moily, Nagaraj S ^b   Kaur, Harpreet ^a   Jajodia, Ajay ^a   Purushottam, Meera ^b   Kukreti, Ritushree ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE RECEPTOR; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN RECEPTOR; ZIPRASIDONE;

DRD1 GENE; DRD2 GENE; DRD3 GENE; DRD4 GENE; DRUG TARGETING; GENETIC VARIABILITY; HTR1A GENE; HTR2A GENE; HTR2C GENE; HTR3A GENE; HTR3B GENE; HUMAN; HUMAN TISSUE; INDIA; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECEPTOR GENE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; GENOTYPE; HUMANS; MOLECULAR TARGETED THERAPY; PHENOTYPE; RECEPTORS, SEROTONIN, 5-HT3; SCHIZOPHRENIA;

EID: 84869029323     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.32105     Document Type: Letter

References (10)

1. Enoch MA, Gorodetsky E, Hodgkinson C, Roy A, Goldman D. 2011. Functional genetic variants that increase synaptic serotonin and 5-HT3 receptor sensitivity predict alcohol and drug dependence. Mol Psychiatry 16: 1139-1146.
2. Gupta M, Bhatnagar P, Grover S, Kaur H, Baghel R, Bhasin Y, Chauhan C, Verma B, Manduva V, Mukherjee O, Purushottam M, Sharma A, Jain S, Brahmachari SK, Kukreti R. 2009. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 10: 385-397.
3. Guy W, Editor. 1976. Clinical global impressions. In: Early Clinical Drug Evaluation Unit (ECDEU) assessment manual for psychopharmacology revised (DHEW Publ No ADM 76-338). Rockville, MD: National Institute of Mental Health. pp 218-222.
4. Krzywkowski K, Davies PA, Feinberg-Zadek PL, Bräuner-Osborne H, Jensen AA. 2008. High-frequency HTR3B variant associated with major depression dramatically augments the signaling of the human 5-HT3AB receptor. Proc Natl Acad Sci USA 105: 722-727.
5. Pritchard JK, Rosenberg NA. 1999. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 65: 220-228.
6. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. 2007. PLINK: A toolset for whole-genome association and population-based linkage analysis. Am J Hum Genet 81: 559-575.
7. Reynolds GP, Arranz B, Templeman LA, Fertuzinhos S, San L. 2006. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry 163: 1826-1829.
8. Schuhmacher A, Mössner R, Quednow BB, Kühn KU, Wagner M, Cvetanovska G, Rujescu D, Zill P, Möller HJ, Rietschel M, Franke P, Wölwer W, Gaebel W, Maier W. 2009. Influence of 5-HT3 receptor subunit genes HTR3A HTR3B HTR3C HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. Pharmacogenet Genomics 19: 843-851.
9. Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. 2010. Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenet Genomics 20: 274-276.
10. van Os J, Kapur S. 2009. Schizophrenia. Lancet 374: 635-645.